Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 16
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Clonal dissemination and plasmid plasticity of KPC-3-producing Klebsiella pneumoniae ST512 during a hospital outbreak in Spain

  • Riesgo-Magaña, María|||0000-0003-0825-9319
  • Moreno Mingorance, Albert|||0000-0002-3073-5046
  • Bueno, Jessica|||0000-0002-4125-8150
  • Arnal, Sara|||0000-0001-8889-6857
  • Alvarado, Elena|||0000-0003-3560-5096
  • González-López, Juanjo|||0000-0003-2419-5909
  • Seral, Cristina|||0000-0002-9742-1463
Purpose: To describe the first outbreak of KPC-3-producing Klebsiella pneumoniae ST512 in Aragón, Spain, and characterize its clinical, microbiological, and genomic features, including plasmid dynamics, resistance mechanisms, and phylogenetic context. Methods: Between July 2022 and July 2024, 130 KPC-3-producing K. pneumoniae isolates were recovered from 33 patients during an outbreak at a tertiary-care hospital in Zaragoza. Antimicrobial susceptibility testing and whole-genome sequencing were performed. Phylogenomic (SNP and cgMLST) and plasmid analyses defined clonal relatedness and plasmid structures. Comparative genomics with 985 international ST512/KPC-3 genomes determined phylogeographic relationships. Results: Most cases (84.6%) were detected through active surveillance. All the isolates were resistant to β-lactams, ceftolozane/tazobactam, tobramycin and amikacin, while 64.4% remained susceptible to gentamicin. All the isolates were susceptible to cefiderocol, colistin, and tigecycline. One ceftazidime/avibactam-resistant isolate carrying bla emerged after prolonged therapy. Genomic analysis confirmed a clonal outbreak of Klebsiella pneumoniae ST512 (≤ 16 SNPs; ≤13 cgMLST allelic differences). Phylogenetic comparison showed that the isolates were genetically close to those from Italy and central Spain. All isolates carried bla within Tn4401b. Three bla plasmid structures were identified: an IncFII(K) plasmid (pHCUKPC3), a ColEST258 variant, and a novel cointegrate plasmid (pHCUKPC3co). The virulence-associated factors identified included yersiniabactin (ybt10/ICEKp4), KL107 capsular type, and O2afg O-antigen. Conclusion: This study documents the wider dissemination of ST512/KPC-3 as a high-risk clone in Spain, characterized by persistence driven by clonal dissemination, selective pressure, and plasmid plasticity. Our findings highlight the need to integrate genomic and plasmidomic surveillance to anticipate resistance evolution and contain high-risk clones.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

A Subset of PD-1-Expressing CD56bright NK Cells Identifies Patients with Good Response to Immune Checkpoint Inhibitors in Lung Cancer

  • Gascón-Ruiz, Marta
  • Ramírez-Labrada, Ariel
  • Lastra, Rodrigo
  • Martínez-Lostao, Luis
  • Paño-Pardo, J. Ramón
  • Sesma, Andrea
  • Zapata-García, María
  • Moratiel, Alba
  • Quílez, Elisa
  • Torres-Ramón, Irene
  • Yubero, Alfonso
  • Domingo, María Pilar
  • Esteban, Patricia
  • Gálvez, Eva M.
  • Pardo, Julián
  • Isla, Dolores
(1) Despite the effectiveness of immune checkpoint inhibitors (ICIs) in lung cancer, there is a lack of knowledge about predictive biomarkers. The objective of our study is to analyze different subsets of T-lymphocytes and natural killer (NK) cells as predictive biomarkers in a cohort of patients with nonsmall cell lung cancer (NSCLC) treated with ICI. (2) This is an observational, prospective study with 55 NSCLC patients treated with ICI. A total of 43 T and NK cell subsets are analyzed in peripheral blood, including the main markers of exhaustion, differentiation, memory, activation, and inhibition. (3) Regarding the descriptive data, Granzyme B+CD4+ Treg lymphocytes stand out (median 17.4%), and within the NK populations, most patients presented cytotoxic NK cells (CD56+CD3−CD16+GranzymeB+; median 94.8%), and about half of them have highly differentiated adaptive-like NK cells (CD56+CD3−CD16+CD57+ (mean 59.8%). A statistically significant difference was observed between the expression of PD1 within the CD56bright NK cell subpopulation (CD56+CD3−CD16−PD-1+) (p = 0.047) and a better OS. (4) Circulating immune cell subpopulations are promising prognostic biomarkers for ICI. Pending on validation with a larger sample, here we provide an analysis of the major circulating T and NK cell subsets involved in cancer immunity, with promising results despite a small sample size.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

CAR immunotherapy for the treatment of infectious diseases: a systematic review

  • Morte-Romea, Elena
  • Pesini, Cecilia
  • Pellejero-Sagastizábal, Galadriel
  • Letona-Giménez, Santiago
  • Martínez-Lostao, Luis
  • Loscos Aranda, Silvia
  • Toyas, Carla
  • Redrado, Sergio
  • Dolader-Ballesteros, Elena
  • Arias, Maykel
  • Galvez, Eva M.
  • Sanz-Pamplona, Rebeca
  • Pardo, Julián
  • Paño-Pardo, Jose Ramón
  • Ramírez-Labrada, Ariel
Immunotherapy treatments aim to modulate the host’s immune response to either mitigate it in inflammatory/autoimmune disease or enhance it against infection or cancer. Among different immunotherapies reaching clinical application during the last years, chimeric antigen receptor (CAR) immunotherapy has emerged as an effective treatment for cancer where different CAR T cells have already been approved. Yet their use against infectious diseases is an area still relatively poorly explored, albeit with tremendous potential for research and clinical application. Infectious diseases represent a global health challenge, with the escalating threat of antimicrobial resistance underscoring the need for alternative therapeutic approaches. This review aims to systematically evaluate the current applications of CAR immunotherapy in infectious diseases and discuss its potential for future applications. Notably, CAR cell therapies, initially developed for cancer treatment, are gaining recognition as potential remedies for infectious diseases. The review sheds light on significant progress in CAR T cell therapy directed at viral and opportunistic fungal infections.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Multiparametric in vitro and in vivo analysis of the safety profile of self-assembling peptides

  • Ramirez-Labrada, Ariel
  • Santiago, Llipsy
  • Pesini, Cecilia
  • Arrieta, Marta
  • Arias, Maykel
  • Calvo Pérez, Adanays
  • Ciulla, Maria Gessica
  • Forouharshad, Mahdi
  • Pardo, Julian
  • Gálvez, Eva M.
  • Gelain, Fabrizio
Self-assembling peptides (SAPs) have gained significant attention in biomedicine because of their unique properties and ability to undergo molecular self-assembly driven by non-covalent interactions. By manipulating their composition and structure, SAPs can form well-ordered nanostructures with enhanced selectivity, stability and biocompatibility. SAPs offer advantages such as high chemical and biological diversity and the potential for functionalization. However, studies concerning its potentially toxic effects are very scarce, a limitation that compromises its potential translation to humans. This study investigates the potentially toxic effects of six different SAP formulations composed of natural amino acids designed for nervous tissue engineering and amenable to ready cross-linking boosting their biomechanical properties. All methods were performed in accordance with the relevant guidelines and regulations. A wound-healing assay was performed to evaluate how SAPs modify cell migration. The results in vitro demonstrated that SAPs did not induce genotoxicity neither skin sensitization. In vivo, SAPs were well-tolerated without any signs of acute systemic toxicity. Interestingly, SAPs were found to promote the migration of endothelial, macrophage, fibroblast, and neuronal-like cells in vitro, supporting a high potential for tissue regeneration. These findings contribute to the development and translation of SAP-based biomaterials for biomedical applications.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Identification of FasL as a crucial host factor driving COVID-19 pathology and lethality

  • Albert, Marie-Christine
  • Uranga-Murillo, Iratxe
  • Arias, Maykel
  • De Miguel, Diego
  • Peña, Natacha
  • Montinaro, Antonella
  • Varanda, Ana Beatriz
  • Theobald, Sebastian J.
  • Areso, Itziar
  • Saggau, Julia
  • Koch, Manuel
  • Liccardi, Gianmaria
  • Peltzer, Nieves
  • Rybniker, Jan
  • Hurtado-Guerrero, Ramón
  • Merino, Pedro
  • Monzón, Marta
  • Badiola, Juan J.
  • Reindl-Schwaighofer, Roman
  • Sanz-Pamplona, Rebeca
  • Cebollada-Solanas, Alberto
  • Megyesfalvi, Zsolt
  • Dome, Balazs
  • Secrier, Maria
  • Hartmann, Boris
  • Bergmann, Michael
  • Pardo, Julián
  • Walczak, Henning
The dysregulated immune response and inflammation resulting in severe COVID-19 are still incompletely understood. Having recently determined that aberrant death-ligand-induced cell death can cause lethal inflammation, we hypothesized that this process might also cause or contribute to inflammatory disease and lung failure following SARS-CoV-2 infection. To test this hypothesis, we developed a novel mouse-adapted SARS-CoV-2 model (MA20) that recapitulates key pathological features of COVID-19. Concomitantly with occurrence of cell death and inflammation, FasL expression was significantly increased on inflammatory monocytic macrophages and NK cells in the lungs of MA20-infected mice. Importantly, therapeutic FasL inhibition markedly increased survival of both, young and old MA20-infected mice coincident with substantially reduced cell death and inflammation in their lungs. Intriguingly, FasL was also increased in the bronchoalveolar lavage fluid of critically-ill COVID-19 patients. Together, these results identify FasL as a crucial host factor driving the immuno-pathology that underlies COVID-19 severity and lethality, and imply that patients with severe COVID-19 may significantly benefit from therapeutic inhibition of FasL.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

The importance of murine phospho-MLKL-S345 in situ detection for necroptosis assessment in vivo

  • Kelepouras, Konstantinos
  • Saggau, Julia
  • Varanda, Ana Beatriz
  • Zrilic, Matea
  • Kiefer, Christine
  • Rakhsh-Khorshid, Hassan
  • Lisewski, Ina
  • Uranga-Murillo, Iratxe
  • Arias, Maykel
  • Pardo, Julian
  • Tonnus, Wulf
  • Linkermann, Andreas
  • Annibaldi, Alessandro
  • Walczak, Henning
  • Liccardi, Gianmaria
Necroptosis is a caspase-independent modality of cell death implicated in many inflammatory pathologies. The execution of this pathway requires the formation of a cytosolic platform that comprises RIPK1 and RIPK3 which, in turn, mediates the phosphorylation of the pseudokinase MLKL (S345 in mouse). The activation of this executioner is followed by its oligomerisation and accumulation at the plasma-membrane where it leads to cell death via plasma-membrane destabilisation and consequent permeabilisation. While the biochemical and cellular characterisation of these events have been amply investigated, the study of necroptosis involvement in vivo in animal models is currently limited to the use of Mlkl−/− or Ripk3−/− mice. Yet, even in many of the models in which the involvement of necroptosis in disease aetiology has been genetically demonstrated, the fundamental in vivo characterisation regarding the question as to which tissue(s) and specific cell type(s) therein is/are affected by the pathogenic necroptotic death are missing. Here, we describe and validate an immunohistochemistry and immunofluorescence-based method to reliably detect the phosphorylation of mouse MLKL at serine 345 (pMLKL-S345). We first validate the method using tissues derived from mice in which Caspase-8 (Casp8) or FADD are specifically deleted from keratinocytes, or intestinal epithelial cells, respectively. We next demonstrate the presence of necroptotic activation in the lungs of SARS-CoV-infected mice and in the skin and spleen of mice bearing a Sharpin inactivating mutation. Finally, we exclude necroptosis occurrence in the intestines of mice subjected to TNF-induced septic shock. Importantly, by directly comparing the staining of pMLKL-345 with that of cleaved Caspase-3 staining in some of these models, we identify spatio-temporal and functional differences between necroptosis and apoptosis supporting a role of RIPK3 in inflammation independently of MLKL versus the role of RIPK3 in activation of necroptosis.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

An agent-based method to estimate 3D cell migration trajectories from 2D measurements: Quantifying and comparing T vs CAR-T 3D cell migration

  • Camacho-Gómez, Daniel
  • Movilla, Nieves
  • Borau, Carlos
  • Martín, Alejandro
  • Oñate Salafranca, Carmen
  • Pardo, Julián
  • Gómez-Benito, María José
  • García-Aznar, José Manuel
Background and objective: Immune cell migration is one of the key features that enable immune cells to find invading pathogens, control tissue damage, and eliminate primary developing tumors. Chimeric antigen receptor (CAR) T-cell therapy is a novel strategy in the battle against various cancers. It has been successful in treating hematological tumors, yet it still faces many challenges in the case of solid tumors. In this work, we evaluate the three-dimensional (3D) migration capacity of T and CAR-T cells within dense collagen-based hydrogels. Quantifying three-dimensional (3D) cell migration requires microscopy techniques that may not be readily accessible. Thus, we introduce a straightforward mathematical model designed to infer 3D trajectories of cells from two-dimensional (2D) cell trajectories. Methods: We develop a 3D agent-based model (ABM) that simulates the temporal changes in the direction of migration with an inverse transform sampling method. Then, we propose an optimization procedure to accurately orient cell migration over time to reproduce cell migration from 2D experimental cell trajectories. With this model, we simulate cell migration assays of T and CAR-T cells in microfluidic devices conducted under hydrogels with different concentrations of type I collagen and validate our 3D cell migration predictions with light-sheet microscopy. Results: Our findings indicate that CAR-T cell migration is more sensitive to collagen concentration increases than T cells, resulting in a more pronounced reduction in their invasiveness. Moreover, our computational model reveals significant differences in 3D movement patterns between T and CAR-T cells. T cells exhibit migratory behavior in 3D whereas that CAR-T cells predominantly move within the plane, with limited movement in the direction. However, upon the introduction of a CXCL12 chemical gradient, CAR-T cells present migration patterns that closely resemble those of T cells. Conclusions: This framework demonstrates that 2D projections of 3D trajectories may not accurately represent real migration patterns. Moreover, it offers a tool to estimate 3D migration patterns from 2D experimental data, which can be easily obtained with automatic quantification algorithms. This approach helps reduce the need for sophisticated and expensive microscopy equipment required in laboratories, as well as the computational burden involved in producing and analyzing 3D experimental data.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Reseña (Review)

In-depth analysis of the interplay between oncogenic mutations and NK cell-mediated cancer surveillance in solid tumors

  • Pesini, Cecilia
  • Artal, Laura
  • Paúl Bernal, Jorge
  • Sánchez Martinez, Diego
  • Pardo, Julián
  • Ramírez-Labrada, Ariel
Natural killer (NK) cells play a crucial role in antitumoral and antiviral responses. Yet, cancer cells can alter themselves or the microenvironment through the secretion of cytokines or other factors, hindering NK cell activation and promoting a less cytotoxic phenotype. These resistance mechanisms, often referred to as the “hallmarks of cancer” are significantly influenced by the activation of oncogenes, impacting most, if not all, of the described hallmarks. Along with oncogenes, other types of genes, the tumor suppressor genes are frequently mutated or modified during cancer. Traditionally, these genes have been associated with uncontrollable tumor growth and apoptosis resistance. Recent evidence suggests oncogenic mutations extend beyond modulating cell death/proliferation programs, influencing cancer immunosurveillance. While T cells have been more studied, the results obtained highlight NK cells as emerging key protagonists for enhancing tumor cell elimination by modulating oncogenic activity. A few recent studies highlight the crucial role of oncogenic mutations in NK cell-mediated cancer recognition, impacting angiogenesis, stress ligands, and signaling balance within the tumor microenvironment. This review will critically examine recent discoveries correlating oncogenic mutations to NK cell-mediated cancer immunosurveillance, a relatively underexplored area, particularly in the era dominated by immune checkpoint inhibitors and CAR-T cells. Building on these insights, we will explore opportunities to improve NK cell-based immunotherapies, which are increasingly recognized as promising alternatives for treating low-antigenic tumors, offering significant advantages in terms of safety and manufacturing suitability.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Antibiotic use and outcome in patients with negative blood cultures, a new target population for antimicrobial stewardship interventions: a prospective multicentre cohort (NO-BACT)

  • Girón Ortega, J.A.
  • Fernández Guerrero, R.
  • Montes de Oca Arjona, M.
  • Sánchez Galán, F.
  • Pellejero Sagastizábal, G.
  • Morte Romea, E.
  • De Cueto, M.
  • Beltrán García, M.
  • Palacios Baena, Z.
  • Jiménez Jorge, S.
  • Rodríguez Baño, J.
  • Retamar Gentil, P.
Objectives: To evaluate the appropriateness of antimicrobial treatment and the risk factors for mortality in patients with negative blood cultures (BC), in order to evaluate whether this population would be a suitable target for antimicrobial stewardship (AMS) interventions. Methods: A multicentre prospective cohort study of patients with negative BC in three Spanish hospitals between October 2018 and July 2019 was performed. The main endpoints were the appropriateness of antimicrobial treatment (evaluated by two investigators according to local guidelines) and 30-day mortality. Cox-regression was performed to estimate the association between variables and 30-day mortality. Results: Of 1011 patients in whom BC was obtained, these were negative in 803 (79%) and were included; 30-day mortality was 9% (70 patients); antibiotic treatment was considered inappropriate in 299 (40%) of 747 patients evaluated at day 2, and in 266 (46%) of 573 at day 5–7. The variables independently associated with increased risk of 30-day mortality were higher age (HR 1.05; 95% CI 1.03–1.07), neoplasia (HR 2.73; 95% CI 1.64–4.56), antibiotic treatment in the 48 h prior to BC extraction (HR 2.06; 95% CI 1.23–3.43) and insufficient antibiotic coverage at day 2 after BC obtainment (HR 2.35; 95% CI 1.39–4.00). Urinary, catheter and biliary sources of infection were associated with lower risk (HR 0.40; 95% CI 0.20–0.81). Conclusions: Antimicrobial treatment is frequently inappropriate among patients with negative BC; insufficient antibiotic coverage at day 2 was associated with mortality. These results suggest that patients with negative BC are a suitable population for AS interventions. Summary: Antimicrobial treatment in patients with negative blood culture was frequently inappropriate, and inappropriate coverage at day 2 was associated with increased risk of death. These data support the consideration of this population as a potential target for antimicrobial stewardship interventions.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Preserved efficacy of lyophilized SARS-CoV-2 mRNA vaccine incorporating novel ionizable lipids after one year at 25 °C

  • Mata, Elena
  • Broset, Esther
  • Matute, Carlos
  • Stoian, Andrei
  • Adame, Susana
  • Alejo, Teresa
  • López, Alexandre
  • Andrés, Beatriz
  • Heredero, Juan
  • de Miguel, Diego
  • Giménez-Warren, Javier
  • Lampaya, Verónica
  • Casabona, Diego
  • Calvo, Alba
  • Quincoces, Gema
  • Peñuelas, Iván
  • Gamazo, Carlos
  • Uranga, Iratxe
  • Peña, Natacha
  • Arias, Maykel
  • Pardo, Julián
  • Moreno, Bernardino
  • Badiola, Juan
  • Martínez-Oliván, Juan
  • Pérez-Herrán, Esther
mRNA vaccines have shown great efficacy against SARS-CoV-2, yet challenges remain in optimizing vaccine components to achieve enhanced immune response and vaccine stability. In this study, we developed CPVax-CoV, a new lyophilized mRNA vaccine that features novel thiolactone-based ionizable lipids and newly designed untranslated regions (UTRs) for enhanced expression. Incorporation of these optimized components into our vaccine candidate CPVax-CoV significantly improved immune responses in mice compared to commercially available mRNA vaccines. Moreover, lyophilized CPVax-CoV has proven to be thermostable, maintaining its biological activity for up to one year at 4 °C and 25 °C after lyophilization, overcoming the cold-chain limitations of current mRNA vaccines. This vaccine demonstrates protective efficacy against ancestral SARS-CoV-2 and the Omicron XBB variant, offering a scalable solution for global distribution and pandemic preparedness. These findings underscore the potential of this platform for future next-generation mRNA vaccine development.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Mutant calreticulin enables potent and selective CAR-T cell therapy in preclinical models of myeloproliferative neoplasms

  • Pesini, Cecilia
  • Gil-Bellido, Mario
  • Millán, Lorena S.
  • Oñate, Carmen
  • Calvo-Pérez, Adanays
  • Santiago, Llipsy
  • Iglesias, Eldris
  • Bernal, Jorge Paúl
  • Araujo-Voces, Miguel
  • Paz Artigas, Laura
  • García-Martínez, Laura
  • Roig, Francisco J
  • Movilla Meno, Nieves
  • Garcia-Aznar, José Manuel
  • Menéndez-Jandula, Bárbara
  • Olave, María Teresa
  • Azaceta Reinares, Gemma
  • Garrote, Marta
  • Alvarez-Larrán, Alberto
  • Gálvez, Eva M
  • Sánchez Martínez, Diego
  • Arias, Maykel A
  • Pardo, Julian
  • Ramirez-Labrada, Ariel
Background The adoptive transfer of T cells engineered to express chimeric antigen receptors (CAR-T) has shown high efficacy and safety in treating various hematologic malignancies. However, many hematologic disorders, such as BCR::ABL1-negative myeloproliferative neoplasms (MPNs), lack effective treatment options. Some of these neoplasms are marked by a recurrent mutation that results in the expression of mutant calreticulin (mCALR), a neoantigen absent in healthy tissues, making it a highly specific and appealing target for CAR-T cell therapy. Methods Five distinct CARs were designed based on available monoclonal antibody sequences that target mCALR and were subsequently used to generate CAR-T cells. The most effective construct was selected through functional in vitro assays against mCALR-positive cell lines. Its efficacy was then evaluated in cell lines, patient-derived cells, and orthotopic xenograft models, assessing tumor burden, CAR-T cell infiltration, and animal survival. Bulk and single-cell RNA sequencing were performed on patient-derived cells and residual tumor cells from CART-treated mice, respectively, to investigate potential resistance mechanisms. The impact of the most relevant pathway alteration on CAR-T efficacy was also analyzed. Pharmacological rescue assays using targeted agents were then conducted. Results Among the five constructs, one demonstrated superior and specific cytotoxicity against mCALR-expressing cells, with no activity against mCALR-negative controls. This CAR-T cell also eliminated patient-derived MPN cells and controlled disease progression in xenograft models, which correlated with the persistence of CAR-T cells and tumor infiltration. Transcriptomic profiling of patient samples and residual tumor cells in spleens of treated mice revealed upregulation of anti-apoptotic proteins. Functional assays confirmed reduced CAR-T efficacy in Bcl-2 high cells, which was restored by co-treatment with venetoclax, indicating a viable combination approach to overcome resistance. Conclusions This study demonstrates, for the first time, the successful targeting of mCALR with CAR-T cells as a therapeutic strategy for MPNs. The chosen construct shows strong preclinical efficacy against established cell lines and patient-derived cells. Additionally, transcriptomic profiling uncovered apoptosis resistance mechanisms and supports a combination strategy with BH3 mimetics, such as venetoclax. These findings provide a compelling rationale for ongoing preclinical development and future clinical application of anti-mCALR CAR-T cells for the treatment of MPNs.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Clonal dissemination and plasmid plasticity of KPC-3–producing Klebsiella pneumoniae ST512 during a hospital outbreak in Spain

  • Riesgo-Magaña, María
  • Moreno-Mingorance, Albert
  • Bueno, Jessica
  • Arnal, Sara
  • Alvarado, Elena
  • González-López, Juan José
  • Seral, Cristina
Purpose To describe the first outbreak of KPC-3-producing Klebsiella pneumoniae ST512 in Aragón, Spain, and characterize its clinical, microbiological, and genomic features, including plasmid dynamics, resistance mechanisms, and phylogenetic context. Methods Between July 2022 and July 2024, 130 KPC-3-producing K. pneumoniae isolates were recovered from 33 patients during an outbreak at a tertiary-care hospital in Zaragoza. Antimicrobial susceptibility testing and whole-genome sequencing were performed. Phylogenomic (SNP and cgMLST) and plasmid analyses defined clonal relatedness and plasmid structures. Comparative genomics with 985 international ST512/KPC-3 genomes determined phylogeographic relationships. Results Most cases (84.6%) were detected through active surveillance. All the isolates were resistant to β-lactams, ceftolozane/tazobactam, tobramycin and amikacin, while 64.4% remained susceptible to gentamicin. All the isolates were susceptible to cefiderocol, colistin, and tigecycline. One ceftazidime/avibactam-resistant isolate carrying blaKPC−70 emerged after prolonged therapy. Genomic analysis confirmed a clonal outbreak of Klebsiella pneumoniae ST512 (≤ 16 SNPs; ≤13 cgMLST allelic differences). Phylogenetic comparison showed that the isolates were genetically close to those from Italy and central Spain. All isolates carried blaKPC−3 within Tn4401b. Three blaKPC−3 plasmid structures were identified: an IncFII(K) plasmid (pHCUKPC3), a ColEST258 variant, and a novel cointegrate plasmid (pHCUKPC3co). The virulence-associated factors identified included yersiniabactin (ybt10/ICEKp4), KL107 capsular type, and O2afg O-antigen. Conclusion This study documents the wider dissemination of ST512/KPC-3 as a high-risk clone in Spain, characterized by persistence driven by clonal dissemination, selective pressure, and plasmid plasticity. Our findings highlight the need to integrate genomic and plasmidomic surveillance to anticipate resistance evolution and contain high-risk clones.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Radiotherapy synergizes with an inducible AAV-based immunotherapy platform to program local and systemic antitumor immunity

  • Marco, Sonia
  • Fernández, Myriam
  • Honorato, Beatriz
  • Juanarena, Nerea
  • Sainz, Cristina
  • Andueza, Ainhoa
  • Gould, David J.
  • Anderson, Seth
  • de Andrea, Carlos
  • Domínguez, Paulo Pérez
  • Wong, Paolo
  • Vásquez, Carlos
  • Narinda, Irene
  • Unzu, Carmen
  • Isola, Sergio
  • Tavira, Beatriz
  • Ariz, Mikel
  • Camps, Gracián
  • Sanmamed, Miguel F.
  • Pardo, Julián
  • Labiano, Sara
  • Alonso, Marta M.
  • Marco-Sanz, Javier
  • Guruceaga, Elizabeth
  • Collantes, María
  • Simón, Jon Ander
  • Peñuelas, Iván
  • Fernández-Irigoyen, Joaquín
  • Santamaría, Enrique
  • Prieto, Jesús
  • Dubrot, Juan
Radiotherapy (RT) can prime the immune system against cancer but often fails to generate effective antitumor responses due to concomitant induction of immunosuppressive factors. To overcome this limitation, we built upon the observation that RT enhances adeno-associated vectors (AAVs) tumor transduction through the epigenetic modification of vector episomes. We designed an AAV-based platform to deliver immunostimulatory cytokines through an interferon (IFN)-inducible promoter that allows for spatial control of transgene expression into irradiated tumors. As opposed to a constitutive system, local delivery of a vector encoding for inducible IL-12 (AAV-iIL12) achieves an efficient production of the cytokine without significant toxicity. Combination of RT and AAV-iIL12 generates a highly immunostimulatory tumor microenvironment (TME) leading to robust local and systemic antitumor responses in an IFNγ- and FAS-dependent manner, able to overcome common immune-evasion mechanisms. Our work shows that radiation coupled with AAV-based immune-gene delivery is an efficient and safe approach to treat cancer.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Circulating granzyme A is elevated within the dysregulated host response and associates with mortality in abdominal sepsis

  • Pellejero-Sagastizabal, Galadriel
  • Esteban, Patricia
  • Letona-Giménez, Santiago
  • Andrés-Tovar, Alejandro
  • Sierra, José Luis
  • Senan-Salinas, Ana
  • Galvez, Eva María
  • Pardo, Julián
  • Morte-Romea, Elena
  • Arias, Maykel
  • Paño-Pardo, José Ramón
Introduction Granzyme A (GzmA) has been identified as a key amplifier of sepsis-related inflammation in experimental models without contributing to pathogen clearance. However, its behavior and clinical relevance in human bacterial sepsis remain unknown. We aimed to characterize circulating GzmA in secondary peritonitis and explore its associations with clinical severity and all-cause mortality. Methods We conducted a single-center prospective cohort study of 42 adults with secondary peritonitis at Lozano Blesa Clinical Hospital (Zaragoza, Spain), with 31 healthy controls. Peripheral blood was obtained at baseline, 24 h, and 48 h. Serum GzmA concentration and activity, GzmB, cytokines, and endothelial and coagulation markers were measured. Analyses included comparisons across Sepsis-3 severity strata and exploratory prognostic models (logistic regression and receiver operating characteristic curves) evaluating associations between baseline biomarkers and mortality. Sensitivity analyses were performed after excluding patients meeting predefined immunosuppression criteria. Results At baseline, GzmA concentrations (2.3-fold, q-value = 5.41×10−12) and GzmA enzymatic activity (q-value = 6.75 × 10-³) were significantly higher in patients than controls, whereas GzmB did not differ (q-value = 0.332). Across baseline severity categories, VCAM-1 showed the clearest gradient (q-value = 0.017), while GzmA concentrations were numerically highest in septic shock (median 165.4 pg/mL). GzmA remained elevated through 48 h, and non-survivors had higher baseline levels than survivors. Each doubling of baseline GzmA was associated with higher overall in-hospital mortality (OR 2.52; 95% CI 1.11-5.75, p=0.028), with associations persisting after adjustment for age and comorbidity. Sensitivity analyses excluding immunosuppressed patients yielded a clearer association between GzmA and baseline severity, and confirmed its association with mortality. Discussion Circulating GzmA, but not GzmB, is markedly upregulated, remains elevated during early follow-up, and is preliminarily associated with mortality-related outcomes. These exploratory findings are consistent with experimental models and support further evaluations of extracellular GzmA to investigate its biological and potential translational relevance in sepsis.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Antimicrobial therapy among hospitalized older adults with suspected infection and negative blood cultures

  • Pellejero-Sagastizabal, Galadriel
  • Morte-Romea, Elena
  • Girón Ortega, José Antonio
  • Paño-Pardo, José Ramón
  • Fernández Guerrero, Raquel
  • Guerrero, Francisca
  • Montes de Oca, Montserrat
  • Jiménez-Jorge, Silvia
  • Palacios-Baena, Zaira R.
  • Rodríguez-Baño, Jesús
  • Retamar-Gentil, Pilar
  • Montes de Oca Arjona, Montserrat
  • Galán Sánchez, Fátima
  • Rodríguez Mateos, María Eugenia
  • Girón-González, José Antonio
  • Martín Aspas, Andrés
  • Sánchez Tembleque, Claudio
  • Guerrero Sánchez, Francisca María
  • Morte-Romea, Elena
  • Pellejero-Sagastizabal, Galadriel
  • Luque Gómez, Pilar
  • Paño-Pardo, José Ramón
  • Sierra, José Luis
  • Letona Gimenez, Santiago
  • Palacián, Pilar
  • Rodriguez, Nora Mariela
  • Arenere Mendoza, Mercedes
  • Allende Bandrés, Maria Ángeles
  • Fresquet Molina, Raquel
  • Navarro Pardo, Irene
  • Girón Ortega, José Antonio
  • Fernández Guerero, Raquel
  • Retamar-Gentil, Pilar
  • Palacios-Baena, Zaira
  • de Cueto, Marina
  • Beltrán García, Margarita
  • Cantón Bulnes, María Luisa
  • Suarti, Lorenzo Roberto
  • Rodríguez-Baño, Jesús
Background Managing infections in older adults is challenging due to their unique characteristics, which often drives empirical antimicrobial use, increasing risks of adverse outcomes and antimicrobial resistance (AMR). Data on antimicrobial adequacy in older patients with suspected infection but negative blood cultures (BC) remain scarce, despite this being a common clinical scenario. Methods In this multicenter prospective cohort study (NO-BACT project) across three Spanish hospitals (2018–2019), we compared antimicrobial therapy adequacy between older adults (≥ 85 years) and younger patients with suspected infections and negative BC. Antimicrobial stewardship (AMS) experts evaluated treatment adequacy at days 2 and 5–7 using standardized guideline-based criteria. We assessed predictors of adequacy using logistic regression and examined clinical outcomes including 30-day mortality and length of hospital stay (LOS). Results Among 799 enrolled patients, 90 (11.3%) were older adults. While initial antimicrobial adequacy was comparable between groups at Day 2 (59.8% vs. 60.1%), older adults were significantly less likely to receive adequate treatment by Days 5–7 (adjusted OR 0.46, 95% CI 0.25–0.82, p = 0.009). The main drivers of inadequacy were excess antimicrobial spectrum (84.2%) and inappropriate route of administration (48.7%). Older adults demonstrated higher 30-day mortality (16.7% vs. 7.8%; p = 0.009) despite shorter LOS (8 vs. 10 days, p = 0.006), though treatment adequacy was not associated with mortality. Conclusions In older patients with negative BC, antimicrobial therapy shows high rates of inadequacy that worsen over time, primarily due to delayed de-escalation and prolonged intravenous therapy. These findings identify a clear target for AMS interventions focusing on timely treatment optimization.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Radiotherapy synergizes with an inducible AAV-based immunotherapy platform to program local and systemic antitumor immunity

  • Marco, Sonia
  • Fernández-Sendin, Myriam
  • Honorato, Beatriz
  • Juanarena, Nerea
  • Sáinz, Cristina
  • Andueza San Miguel, Ainhoa
  • Gould, David J.
  • Anderson, Seth
  • Andrea, Carlos de
  • Pérez Domínguez, Paulo
  • Wong, Paolo
  • Vásquez, Carlos
  • Narinda, Irene
  • Unzu, Carmen
  • Isola, Sergio
  • Tavira, Beatriz
  • Ariz Galilea, Mikel
  • Camps, Gracián
  • Sanmamed, Miguel F.
  • Pardo, Julián
  • Labiano, Sara
  • Alonso, Marta M.
  • Marco-Sanz, Javier
  • Guruceaga, Elizabeth
  • Collantes, María
  • Simón, Jon Ander
  • Peñuelas, Iván
  • Fernández Irigoyen, Joaquín
  • Santamaría Martínez, Enrique
  • Prieto, Jesús
  • Dubrot, Juan
Radiotherapy (RT) can prime the immune system against cancer but often fails to generate effective antitumor responses due to concomitant induction of immunosuppressive factors. To overcome this limitation, we built upon the observation that RT enhances adeno-associated vectors (AAVs) tumor transduction through the epigenetic modification of vector episomes. We designed an AAV-based platform to deliver immunostimulatory cytokines through an interferon (IFN)-inducible promoter that allows for spatial control of transgene expression into irradiated tumors. As opposed to a constitutive system, local delivery of a vector encoding for inducible IL-12 (AAV-iIL12) achieves an efficient production of the cytokine without significant toxicity. Combination of RT and AAV-iIL12 generates a highly immunostimulatory tumor microenvironment (TME) leading to robust local and systemic antitumor responses in an IFNγ- and FAS-dependent manner, able to overcome common immune-evasion mechanisms. Our work shows that radiation coupled with AAV-based immune-gene delivery is an efficient and safe approach to treat cancer., This work was supported by grants PID2024-160227OB-I00 (funded by MICIU/AEI/10.13039/501100011033 and FEDER, EU), NAIARA Project (ref. 0011-1411-2025-000144, funded by Gobierno de Navarra and FEDER 2021-2027), PID2020-113963RBI00 from AEI, Aragon Government (B29-20R) and CIBERINFEC/Instituto de Salud Carlos III, (CB21/13/00087).